Provectus Biopharmaceuticals, Inc. (PVCT) Stock Price & Analysis
Provectus Biopharmaceuticals, Inc. (PVCT) rose 0.00% to USD 0.06 as of July 25, 2026 at 06:10 UTC, according to Nexqual real-time market data.
PVCT last closed at USD 0.06; the session ranged USD 0.06–0.07 on volume of 82,805 shares. Market capitalization is $26.06M, with a 52-week range of USD 0.04–0.11 (OQB). Source: Nexqual, July 25, 2026 at 06:10 UTC.
Key Statistics (as of July 25, 2026 at 06:10 UTC)
| Price | USD 0.06 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.06 |
| Open | USD 0.06 |
| Day Range | USD 0.06 – 0.07 |
| 52-Week Range | USD 0.04 – 0.11 |
| Volume | 82,805 shares |
| Market Cap | $26.06M |
| Exchange | OQB |
Technical Analysis (PVCT)
Nexqual's technical model rates PVCT "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.32 (neutral) |
| vs SMA50 | Below (USD 0.07) |
| MACD | -0 (negative) |
Analyst Ratings (PVCT)
Wall Street analysts rate PVCT "None", per Nexqual as of July 25, 2026 at 06:10 UTC.
| Consensus Rating | None |
|---|
Earnings (PVCT)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2012-12-31 | USD -0.02 vs est -0.03 ▲ beat |
| 2012-09-30 | USD -0.02 vs est -0.03 ▲ beat |
| 2012-06-30 | USD -0.03 vs est -0.03 ▲ beat |
| 2012-03-31 | USD -0.04 vs est -0.04 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financials & Fundamentals (PVCT)
| Total Revenue | $57,480 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -8688.64% |
| Profit Margin | +0.00% |
| Current Ratio | 0.06 |
| Total Cash | $223,883 |
| Total Debt | $2.77M |
| Free Cash Flow | $-609,803 |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financial Health Score (PVCT)
Nexqual rates Provectus Biopharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $224K cash vs $3M debt |
| Cash Flow | Weak — Operating cash flow -$3M |
| Efficiency | Mixed — No data |
Ownership (PVCT)
| Insider Ownership | +7.48% |
|---|---|
| Institutional Ownership | +0.05% |
| Shares Outstanding | 420.28M |
| Float | 387.95M |
| Short % of Float | +0.78% |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Leadership (PVCT)
Provectus Biopharmaceuticals, Inc. is led by Edward V. Pershing (age 72), CEO & Executive Chairman of Board, per Nexqual as of July 25, 2026 at 06:10 UTC.
| CEO & Executive Chairman of Board | Edward V. Pershing (age 72) |
|---|---|
| President & Executive Vice Chairman of the Board | Dominic Rodrigues C.F.A. (age 56) |
| Co-Founder & CTO | Eric A. Wachter (age 62) |
| Chief Financial Officer | Heather Raines (age 58) |
From Provectus Biopharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States.
- The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes.
- Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.
- The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMUC | EOM Pharmaceutical Holdings Inc | USD 0.21 | ▼ 15.73% |
| NAVBQ | Navidea Biopharmaceuticals, Inc. | USD 0 | ▲ 0% |
| NWBO | Northwest Biotherapeutics, Inc. | USD 0.17 | ▲ 0% |
| TLOG | TETRALOGIC PHARMACEUTICALS CORP | USD 0 | ▲ 0% |
| ACUR | ACURA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:10 UTC. This page is informational and not investment advice.